Koch Pedro, Schilling Julian, Läubli Marlène, Mitscherlich Florian, Melchart Dieter, Bellucci Sergio
Viterio-Schweiz, St. Gallen, Switzerland.
Int J Technol Assess Health Care. 2009 Jul;25 Suppl 1:174-7. doi: 10.1017/S0266462309090606. Epub 2009 Jun 18.
To review Switzerland's mixed public and private healthcare system with regard to health technology assessment (HTA).
In the past, remarkable work in HTA was done. Accomplishments include the following: (i) Switzerland became an early member of the International Network of Agencies for Health Technology Assessment. (ii) HTA has its legal bases in terms of effectiveness, appropriateness, and efficiency. (iii) The federal law allows the introduction of new technologies for a limited time for evaluation. (iv) A Swiss Network for Health Technology Assessment was established. In 2004, federal HTA activities moved from the Swiss Federal Office "of Social Security" to the one for "Public Health." The Office mainly mandates, manages, and coordinates evaluations attached to its prevention and intervention sections in the fields of AIDS, illegal drugs, and legal drugs.
Because of the absence of a governmental institution assessing and reporting on new health technologies, private and for profit organizations became more important for the decision-making processes. In a regulated market, the implications may be crucial for the public health.
回顾瑞士公私混合医疗体系在卫生技术评估(HTA)方面的情况。
过去,在卫生技术评估方面开展了卓越工作。成果包括:(i)瑞士成为卫生技术评估机构国际网络的早期成员。(ii)卫生技术评估在有效性、适宜性和效率方面有其法律基础。(iii)联邦法律允许在有限时间内引入新技术进行评估。(iv)成立了瑞士卫生技术评估网络。2004年,联邦卫生技术评估活动从瑞士联邦社会保障办公室转移至公共卫生办公室。该办公室主要负责其在艾滋病、非法药物和合法药物领域预防与干预部门相关评估的授权、管理及协调工作。
由于缺乏评估和报告新卫生技术的政府机构,私营和营利性组织在决策过程中变得更为重要。在一个受监管的市场中,这可能对公众健康产生关键影响。